GAMMA Investing’s Actuate Therapeutics ACTU Stock Holding History

GAMMA Investing’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-65	Closed	-$99	–	4412
2026 Q2	$99	Sell	65 -221	-77%	-$512	﹤0.01%	4114
2026 Q1	$784	Buy	+286	New	+$1.18K	﹤0.01%	3885

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's ACTU Position: Q3 2026 in Review

GAMMA Investing sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 65 shares — an estimated $99 sold.

GAMMA Investing first reported a position in ACTU in Q1 2026 and held it in 2 quarters. The position peaked at $784 in Q1 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

GAMMA Investing reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 65 Actuate Therapeutics shares in Q3 2026, an estimated $99.
GAMMA Investing first reported a position in Actuate Therapeutics in Q1 2026 and held it in 2 quarters.
GAMMA Investing's Actuate Therapeutics position peaked at $784 in Q1 2026.
5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.